These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32835735)

  • 1. Discovery of small extracellular vesicle proteins from human serum for liver cirrhosis and liver cancer.
    Uzzaman A; Zhang X; Qiao Z; Zhan H; Sohail A; Wahid A; Shang Z; Guan X; Cao CX; Xiao H
    Biochimie; 2020 Oct; 177():132-141. PubMed ID: 32835735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic analysis of small extracellular vesicles from the plasma of patients with hepatocellular carcinoma.
    Dong W; Xia Z; Chai Z; Qiu Z; Wang X; Yang Z; Wang J; Zhang T; Zhang Q; Jin J
    World J Surg Oncol; 2022 Dec; 20(1):387. PubMed ID: 36471393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of candidate biomarkers from plasma-derived extracellular vesicles of patients with cirrhosis and hepatocellular carcinoma: an exploratory proteomic study.
    Zertuche-Martínez C; Velázquez-Enríquez JM; González-García K; Santos-Álvarez JC; Romero-Tlalolini MLÁ; Pina-Canseco S; Pérez-Campos Mayoral L; Muriel P; Villa-Treviño S; Baltiérrez-Hoyos R; Arellanes-Robledo J; Vásquez-Garzón VR
    Mol Omics; 2024 Aug; 20(7):483-495. PubMed ID: 39011654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.
    Julich-Haertel H; Urban SK; Krawczyk M; Willms A; Jankowski K; Patkowski W; Kruk B; Krasnodębski M; Ligocka J; Schwab R; Richardsen I; Schaaf S; Klein A; Gehlert S; Sänger H; Casper M; Banales JM; Schuppan D; Milkiewicz P; Lammert F; Krawczyk M; Lukacs-Kornek V; Kornek M
    J Hepatol; 2017 Aug; 67(2):282-292. PubMed ID: 28267620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis.
    Saito Y; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
    Oncol Rep; 2010 May; 23(5):1325-30. PubMed ID: 20372847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating microRNA-200 Family as Diagnostic Marker in Hepatocellular Carcinoma.
    Dhayat SA; Hüsing A; Senninger N; Schmidt HH; Haier J; Wolters H; Kabar I
    PLoS One; 2015; 10(10):e0140066. PubMed ID: 26447841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The trajectory of vesicular proteomic signatures from HBV-HCC by chitosan-magnetic bead-based separation and DIA-proteomic analysis.
    Cao L; Zhou Y; Lin S; Yang C; Guan Z; Li X; Yang S; Gao T; Zhao J; Fan N; Song Y; Li D; Li X; Li Z; Guan F; Tan Z
    J Extracell Vesicles; 2024 Sep; 13(9):e12499. PubMed ID: 39207047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease.
    Gray J; Chattopadhyay D; Beale GS; Patman GL; Miele L; King BP; Stewart S; Hudson M; Day CP; Manas DM; Reeves HL
    BMC Cancer; 2009 Aug; 9():271. PubMed ID: 19656391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
    Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
    PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of human hepatocellular carcinoma-related proteins by proteomic approaches.
    Yang MH; Tyan YC; Jong SB; Huang YF; Liao PC; Wang MC
    Anal Bioanal Chem; 2007 Jun; 388(3):637-43. PubMed ID: 17447055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibulin-4 as a potential extracellular vesicle marker of fibrosis in patients with cirrhosis.
    Kumagai M; Tsuchiya A; Yang Y; Takeda N; Natsui K; Natusi Y; Tomiyoshi K; Yamazaki F; Koseki Y; Shinchi H; Imawaka N; Ukekawa R; Nishibu T; Abe H; Sasaki T; Ueda K; Terai S
    FEBS Open Bio; 2024 Aug; 14(8):1264-1276. PubMed ID: 38853023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of serum angiotensin-converting enzyme as a tumour marker of hepatocellular carcinoma.
    Kardum D; Huskic J; Fabijanic D; Banic M; Buljevac M; Kujundzic M; Loncar B
    Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1209-13. PubMed ID: 10563528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.
    Cui J; Kang X; Dai Z; Huang C; Zhou H; Guo K; Li Y; Zhang Y; Sun R; Chen J; Li Y; Tang Z; Uemura T; Liu Y
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):825-34. PubMed ID: 17516088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

  • 16. Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma.
    Han J; Han ML; Xing H; Li ZL; Yuan DY; Wu H; Zhang H; Wang MD; Li C; Liang L; Song YY; Xu AJ; Wu MC; Shen F; Xie Y; Yang T
    Int J Cancer; 2020 Mar; 146(6):1741-1753. PubMed ID: 31361910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry.
    Passos-Castilho AM; Carvalho VM; Cardozo KH; Kikuchi L; Chagas AL; Gomes-Gouvêa MS; Malta F; de Seixas-Santos Nastri AC; Pinho JR; Carrilho FJ; Granato CF
    BMC Cancer; 2015 Dec; 15():985. PubMed ID: 26680993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection.
    Deng H; Fan X; Wang X; Zeng L; Zhang K; Zhang X; Li N; Han Q; Lv Y; Liu Z
    Sci Rep; 2020 Nov; 10(1):20276. PubMed ID: 33219288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma.
    Kalinich M; Bhan I; Kwan TT; Miyamoto DT; Javaid S; LiCausi JA; Milner JD; Hong X; Goyal L; Sil S; Choz M; Ho U; Kapur R; Muzikansky A; Zhang H; Weitz DA; Sequist LV; Ryan DP; Chung RT; Zhu AX; Isselbacher KJ; Ting DT; Toner M; Maheswaran S; Haber DA
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1123-1128. PubMed ID: 28096363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LC-MS profiling of N-Glycans derived from human serum samples for biomarker discovery in hepatocellular carcinoma.
    Tsai TH; Wang M; Di Poto C; Hu Y; Zhou S; Zhao Y; Varghese RS; Luo Y; Tadesse MG; Ziada DH; Desai CS; Shetty K; Mechref Y; Ressom HW
    J Proteome Res; 2014 Nov; 13(11):4859-68. PubMed ID: 25077556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.